We evaluated the efficacy of CK6, a KIT monoclonal antibody, in a panel of human gastrointestinal stromal tumor (GIST) xenograft models. Nude mice were bilaterally transplanted with human GIST xenografts (four patient derived and two cell line derived), treated for 3 weeks, and grouped as follows: control (untreated); CK6 (40 mg/kg, 3× weekly); imatinib (50 mg/kg, twice daily); sunitinib (40 mg...

The activity of the receptor tyrosine kinase KIT is crucial for gastrointestinal stromal tumor (GIST) growth and survival. Imatinib and sunitinib are very effective in advanced GIST, but have no curative potential. The observation that heat shock protein 90 (HSP90) inhibition results in KIT degradation prompted us to assess the efficacy of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504...

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Current therapeutic options include surgery and targeted molecular approaches such as imatinib and sunitinib. Our aim was to establish patient-derived GIST xenografts for the use of screening new drugs and improving current treatment regimens used in GIST. In this present study, we investig...

Abstract Introduction The gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of tract. Even though it can be found in any location digestive tract, colorectal GIST rare. With this study, we aim to review current knowledge regarding prognosis and management GIST. Methods A literature search was conducted PubMed, 717 articles were collected. After analyzing these studie...

Reprint requests to: Dr. Chung-Yi Wang Department of Emergency Medicine, Mackay Memorial Hospital, Taitung Branch. No. 1, Lane 303, Changsha Street, Taitung, Taiwan, R.O.C. This study describes the case of a previously healthy 51-year-old male patient who complained of sudden abdominal pain. Physical examinations revealed overt peritonitis, and computed tomography showed a hypervascular solid t...

INTRODUCTION The PI3K signaling pathway drives tumor cell proliferation and survival in gastrointestinal stromal tumor (GIST). We tested the in vivo efficacy of three PI3K inhibitors (PI3Ki) in patient-derived GIST xenograft models. EXPERIMENTAL DESIGN One hundred and sixty-eight nude mice were grafted with human GIST carrying diverse KIT genotypes and PTEN genomic status. Animals were dosed ...

Gastrointestinal stromal tumors (GIST) are characterized by activating mutations of KIT or platelet-derived growth factor receptor α(PDGFRA), which can be therapeutically targeted by tyrosine kinase inhibitors (TKI) such as imatinib. Despite long-lasting responses, most patients eventually progress after TKI therapy. The calcium-dependent chloride channel DOG1 (ANO1/TMEM16A), which is strongly ...

Gastrointestinal stromal tumor (GIST) is the most frequent mesenchymal tumor of the gastrointestinal tract and one of the most frequent sarcoma. Mutually exclusive KIT and PDGFRA mutations are central events in GIST pathogenesis, and their understanding is crucial because specific treatment targeting oncogenic KIT and PDGFRA activation (especially imatinib) has become available. The most freque...

Treatment for metastatic gastrointestinal stromal tumor (GIST) is a challenge, particularly in pregnant female because of the absence of safety data concerning imatinib use during pregnancy. We report a case of metastatic GIST surgically resected during pregnancy with a favorable outcome. A treatment strategy for GIST in pregnant patients should be carefully discussed by a multidisciplinary tea...

Aim: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal neoplasia of gastrointestinal system. Radical surgery with negative margin is important step for treatment GIST. The primary aim this study was to evaluate risk factors recurrence in patients who underwent diagnosis Secondary reveal that affect survival. Materials and Methods: data 28 GIST our clinic between January 201...